Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis

被引:66
|
作者
Schiff, MH
Whelton, A
机构
[1] Univ Colorado, Sch Med, Denver, CO USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
关键词
drug-drug interactions; renal toxicity; DMARDs; rheumatoid arthritis;
D O I
10.1053/sarh.2000.16641
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To provide a review of the renal toxicity of disease-modifying antirheumatic drugs (DMARDs) currently used for the treatment of rheumatoid arthritis. Methods: Papers in American and European medical journals related to renal toxicity of DMARDs used for the treatment of rheumatoid arthritis were reviewed. Specific DMARDs reviewed were cyclosporine, gold, D-penicillamine, methotrexate, azathioprine, antimalarials, sulfasalazine, leflunomide, etanercept, infliximab, and DMARD combination therapy. Results: The renal toxicity of DMARDs varies widely. Cyclosporine, gold, and D-penicillamine all have a serious potential for renal side effects, particularly in the elderly or in patients with compromised renal function. Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the potential for renal damage. In contrast, methotrexate, azathioprine, antimalarials, sulfasalazine, leflunomide, etanercept, and infliximab have relatively little renal toxicity. Conclusions: The potential for renal toxicity should always be considered when determining which DMARD to use for RA therapy. DMARDs that combine efficacy with negligible renal adverse effects should be used for the treatment of patients susceptible to DMARD-associated renal damage. Semin Arthritis Rheum 30:196-208. Copyright (C) 2000 by W.B. Saunders Company.
引用
收藏
页码:196 / 208
页数:13
相关论文
共 50 条
  • [1] Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs
    Sizova, Lyudmila
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (02) : 173 - 178
  • [2] Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Rosales Rosado, Zulema
    Leon, Leticia
    Freites Nunez, Dalifer
    Font Urgelles, Judit
    Leon Cardenas, Cynthia Milagros
    Vadillo Font, Cristina
    Rodriguez Rodriguez, Luis
    Jover Jover, Juan A.
    Abasolo Alcazar, Lydia
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [3] Disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: Medical education
    Top, Cihan
    Terekeci, Hakan
    TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2008, 28 (03): : 387 - 398
  • [4] Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients
    Mittal, Niti
    Mittal, Rakesh
    Sharma, Aman
    Jose, Vinu
    Wanchu, Ajay
    Singh, Surjit
    SINGAPORE MEDICAL JOURNAL, 2012, 53 (08) : 532 - 536
  • [5] The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Ozen, Gulsen
    Pedro, Sofia
    Michaud, Kaleb
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (05) : 648 - 655
  • [7] Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis
    Di Munno, O
    Delle Sedie, A
    Rossini, A
    Adamil, S
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (02) : 137 - 144
  • [8] Conventional disease-modifying antirheumatic drugs to treat rheumatoid arthritis
    Rath, T.
    Sander, O.
    Rubbert, A.
    DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 657 - 663
  • [9] Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
    Xia, Yunfei
    Yin, Rulan
    Fu, Ting
    Zhang, Lijuan
    Zhang, Qiuxiang
    Guo, Genkai
    Li, Liren
    Gu, Zhifeng
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 735 - 742
  • [10] ANNUAL TREATMENT COST OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Hosseini, R.
    Brown, L. M.
    Fleming, M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2024, 27 (06) : S110 - S110